

H K E c a e a d C e a L e d a d T e S c E c a e H K
 L e d a e e b e c e a c e e , a e
 e e e a a a c c a c c e e e a d e e d c a a a b
 a e e a e e a e a c e e e a
 a e c e a c e e .



SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
(深圳市海普瑞藥業集團股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 9989)

VOLUNTARY ANNOUNCEMENT
“EXARANE” OBTAINS APPROVAL FROM
NEW ZEALAND

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the **Company**, together with its subsidiaries, the **Group**) is pleased to announce that the Company's subsidiary, Hepalink (New Zealand) Limited (the **Company**), has obtained approval from the New Zealand Medicines and Medical Devices Regulatory Authority (the **Authority**) for the registration of Exarane (the **Product**) in New Zealand.

The **Product** is a combination of Exarane and Placebo. The **Product** is used for the treatment of acute pain in patients with moderate to severe pain. The **Product** is available in the following strengths: 20 mg/0.2 mL, 40 mg/0.4 mL, 60 mg/0.6 mL, 80 mg/0.8 mL, 100 mg/mL, 120 mg/0.80 mL, 150 mg/mL.

DETAILS OF THE LICENSE

- (I) **Product Name:** Exarane
- (II) **Dosage Form:** Oral solution
- (III) **Strengths:** 20 mg/0.2 mL, 40 mg/0.4 mL, 60 mg/0.6 mL, 80 mg/0.8 mL, 100 mg/mL, 120 mg/0.80 mL, 150 mg/mL

BENEFIT AND IMPACT TO THE COMPANY

The document discusses the benefits and impact to the company, mentioning the company name 'G...'. The text is partially obscured by a watermark.

A...

B... B...
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Li Li
C a a

28, 2024

A a e da e a ce e , e e ec e d ec e C a a e M . L
L , M . L Ta , M . S a Y a d M . Z a P ; a d e de e de -e ec e
d ec e C a a e D . L C a , M . Wa Pa a d M . Y M .